MAP2K7 and plasma cell myeloma: By Western blot analysis on primary myeloma plasma cells, 12/16 (75.0%) RRMM patients showed phospho-ERK1/2, indicating constitutive activation of the RAS-RAF-MEK-ERK signalling pathway (Fig. 1A and Table 1).